368.50
+0.93%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biocon
Its shares trade on NSE under the ticker BIOCON.NS. It has been listed since 17 April 2004. In the fiscal year to 31 March 2025, it reported revenue of ₹152.62bn and net income of ₹10.13bn. At that date it held total assets of ₹587.97bn and shareholders' equity of ₹216.44bn.
Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2004-04-17. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. The company has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. The company has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Apr 2004
- Employees
- 3,408
- Website
- biocon.com ↗
Leadership
Pay as last reported
- Ms. Kiran Mazumdar-ShawExecutive Chairperson of the Board, since 2020₹42.3m
- Mr. Siddharth MittalChief Executive Officer, Managing Director, Executive Director, since 2014₹73.7m
- Mr. Mukesh KamathInterim Chief Financial Officer
- Mr. Shreehas TambeChief Executive Officer, Managing Director - Biocon Biologics Limited
- Mr. Arun GuptaChief Operating Officer
- Mr. Manoj PananchukunnathChief Scientific Officer, since 2024
- Mr. Rajesh ShanoyCompliance Officer, Company Secretary
- Mr. Amit KaptainHead - Commercial API
- Mr. Vishal NayyarHead - Supply Chain Management
- Ms. Maninder PuriHead - Human Resources
- Mr. Nitin TiwariHead - Quality
- Mr. Abhijit ZutshiChief Commercial Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 94
- Environment
- 99
- Social
- 99
- Governance
- 83
- Direct emissions (scope 1)
- 38,428 t
- Energy emissions (scope 2)
- 116,989 t
- Value chain emissions (scope 3)
- 126,110 t
- Women in the workforce
- 25%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biocon Ltd. develops novel biologics and biosimilars in India and global markets.
- Biocon's API portfolio includes cardiology, anti-diabetics, and oncology products.
- Biocon has five facilities in Bangalore, Hyderabad, and Visakhapatnam for manufacturing.
Weaknesses
- Biocon's API manufacturing relies on complex technology platforms like fermentation and synthesis.
- Biocon's generics segment focuses on the US, Europe, and emerging markets.
- Biocon's research services segment supports biologics and biosimilars development.
Opportunities
- Biocon's novel biologics and biosimilars expand in global markets.
- Biocon's API portfolio targets cardiology and anti-diabetic markets.
- Biocon's facilities in Bangalore, Hyderabad, and Visakhapatnam support growth.
Threats
- Biocon faces competition in the Indian biotechnology sector.
- Biocon's API manufacturing depends on complex technology platforms.
- Biocon's generics segment operates in competitive US and European markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.